Form 4: Veracyte Director Executes Stock Option and Sells Shares Under 10b5-1 Plan

Veracyte director Robert S. Epstein exercised stock options and sold shares on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On November 12, 2024, Veracyte director Robert S. Epstein exercised stock options to acquire 15,000 shares of common stock at a price of $8.04 per share.
• Concurrently, Mr. Epstein sold 15,000 shares of common stock at a weighted average price of $38.322 per share, with individual sale prices ranging from $38.00 to $38.73.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Mr. Epstein on August 9, 2024.
• Following these transactions, Mr. Epstein directly owns 44,598 shares of Veracyte common stock and 20,000 stock options.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine filing related to insider trading activity, which is common for directors and officers of publicly traded companies. The use of a 10b5-1 plan indicates a pre-planned trading strategy to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to manage their personal finances while avoiding potential conflicts of interest.
• The reported transactions are typical for directors who receive stock options as part of their compensation.
• Similar filings are regularly made by directors and officers of other publicly traded companies such as Exact Sciences (EXAS) and Genomic Health (GHDX) when they exercise options or sell shares.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.

Key Dates

Keywords

Veracyte, stock options, insider trading, Form 4, Rule 10b5-1, share sale, director, equity securities